MAPT and Alzheimer disease: In particular, by combining CSF Aβ42, T-tau and P-tau181, a higher diagnostic accuracy for identification of AD from non-AD dementia, as well as the prediction of progression to AD in patients with Mild Cognitive Impairment (MCI), can be reached [3].